|
1
|
Lv Y, Luo X, Xie Z, Qiu J, Yang J, Deng Y, Long R, Tang G, Zhang C, Zuo J. Prospects and challenges of CAR-T cell therapy combined with ICIs. Front Oncol 2024; 14:1368732. [PMID: 38571495 PMCID: PMC10989075 DOI: 10.3389/fonc.2024.1368732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 03/04/2024] [Indexed: 04/05/2024] Open
Abstract
Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology. Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.
Collapse
Affiliation(s)
- Yufan Lv
- The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China
| | - Xinyu Luo
- The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China
| | - Zhuoyi Xie
- Transformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China
| | - Jieya Qiu
- Transformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China
| | - Jinsai Yang
- Computer Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China
| | - Yuqi Deng
- Transformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China
| | - Rou Long
- Transformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China
| | - Guiyang Tang
- Transformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China
| | - Chaohui Zhang
- The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China
| | - Jianhong Zuo
- The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China
- Transformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China
- Computer Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China
- The Third Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China
| |
Collapse
|
|
2
|
Luo X, Zhang J, Guo C, Jiang N, Zhang F, Jiao Q, Xu K, Yang J, Qu G, Lv XB, Zhang Z. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/AKT/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells. Gene 2024; 898:148110. [PMID: 38151177 DOI: 10.1016/j.gene.2023.148110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Revised: 12/20/2023] [Accepted: 12/21/2023] [Indexed: 12/29/2023]
Abstract
The treatment of osteosarcoma patients exhibits individual variability, underscoring the critical importance of targeted therapy. Although (Solute carrier family 35 member A2) SLC35A2's role in the progression of various cancers has been extensively investigated, its specific implications in osteosarcoma remain unexplored. Leveraging data from the (The Cancer Genome Atlas) TCGA and (Genotype-Tissue Expression) GTEx databases, we have discerned that SLC35A2 is notably upregulated in osteosarcoma and correlates with the prognosis of osteosarcoma patients. Consequently, it becomes imperative to delve into the role of SLC35A2 in the context of osteosarcoma. Our research substantiates that SLC35A2 exerts a notable influence on mitochondrial autophagy in osteosarcoma, thereby exerting cascading effects on the proliferation, migration, invasion, and apoptosis of osteosarcoma cells. Mechanistically, SLC35A2 orchestrates mitochondrial autophagy via the PI3K/AKT/mTOR signaling pathway. Moreover, we have conducted rigorous animal experiments to further corroborate the repercussions of SLC35A2 on osteosarcoma growth. In summation, our study elucidates that SLC35A2's modulation of mitochondrial autophagy through the PI3K/AKT/mTOR signaling pathway constitutes a pivotal factor in the malignant progression of osteosarcoma, unveiling promising therapeutic targets for patients grappling with this condition.
Collapse
Affiliation(s)
- Xiaohui Luo
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Department of Orthopedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330008, China; Nanchang Key Laboratory of Orthopaedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Medical Department of Graduate School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China
| | - Jiongfeng Zhang
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Department of Orthopedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330008, China; Nanchang Key Laboratory of Orthopaedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Medical Department of Graduate School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China
| | - Chong Guo
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Department of Orthopedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330008, China; Nanchang Key Laboratory of Orthopaedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Medical Department of Graduate School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China
| | - Ning Jiang
- Institute of Integrative Medicine, Dalian Medical University, Dalian, Liaoning, China
| | - Feifei Zhang
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China
| | - Quahui Jiao
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China
| | - Kai Xu
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Department of Orthopedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330008, China; Nanchang Key Laboratory of Orthopaedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Medical Department of Graduate School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China
| | - Jun Yang
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China
| | - Gaoyang Qu
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Department of Orthopedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330008, China; Nanchang Key Laboratory of Orthopaedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Medical Department of Graduate School, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, China
| | - Xiao-Bin Lv
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
| | - Zhiping Zhang
- Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China; Department of Orthopedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330008, China; Nanchang Key Laboratory of Orthopaedics, The first hospital of Nanchang, The Third Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, China.
| |
Collapse
|